Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045772 | 0.89 | ESR2 (0.45) | ESR2GPR119CYP3A4CYP2C9ESR1 | |
| SCHEMBL13906346 | 0.82 | ESR2 (0.59) | ESR2GPR119SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8483087 | 0.79 | ALDH1A1 (0.46) | SLC6A4SLC6A2SLC6A3MAPT | |
| SCHEMBL20884549 | 0.78 | QDPR (0.51) | GPR119SLC6A4SLC6A2SLC6A3MAPT | |
| SCHEMBL13906351 | 0.77 | ESR2 (0.42) | ESR2GPR119CYP3A4CYP2C9ESR1 | |
| SCHEMBL13906347 | 0.77 | ESR2 (0.42) | ESR2GPR119CYP3A4CYP2C9ESR1 | |
| SCHEMBL10062044 | 0.77 | ESR2 (0.65) | ESR2CYP3A4CYP2C9KCNH2HRH3 | |
| SCHEMBL5584921 | 0.76 | SLC18A3 (0.55) | SLC18A3SLC6A4SLC6A2 | |
| SCHEMBL8317126 | 0.76 | NISCH (0.37) | ESR2GPR119SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL4505629 | 0.74 | SLC18A3 (0.53) | SLC18A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | ESR2 1508/4885GPR119 224/4885CYP3A4 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.